Intarcia Therapeutics Obtains $200,000,000 New Round

  • Feed Type
  • Date
    4/1/2014
  • Company Name
    Intarcia Therapeutics
  • Mailing Address
    155 Seaport Boulevard 11th Floor Boston, MA 02210 USA
  • Company Description
    Intarcia Therapeutics Inc, a privately held pharmaceutical company, is developing therapies for the treatment of cancer, immunological, and infectious diseases.
  • Website
    http://www.intarcia.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $200,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    In this latest transaction, Intarcia further retains control of its lead product candidate ITCA 650 – its novel once-yearly GLP-1 for type two diabetes, currently being investigated in a global phase 3 clinical trial program called FREEDOM.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy